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Abstract
Background
Colorectal cancer (CRC) is one of the most common cancers in the western world. Screen-
ing is an efficient method of reducing cancer-related mortality. Molecular biomarkers for
cancer in general and CRC in particular have been proposed, and hypermethylated DNA
from stool or blood samples are already implemented as biomarkers for CRC screening.
We aimed to evaluate the performance of proven hypermethylated DNA promoter
regions as plasma based biomarkers for CRC detection.
Methods
We conducted a cross-sectional case-control study of 193 CRC patients and 102 colonos-
copy-verified healthy controls. Using methylation specific polymerase chain reaction, we
evaluated 30 DNA promoter regions previously found to be CRC specific. We used multivar-
iable logistic regression with stepwise backwards selection, and subsequent leave-pair-out
cross validation, to calculate the optimism corrected area under the receiver operating char-
acteristics curve (AUC) for all stage as well as early stage CRC.
Results
None of the individual DNA promoter regions provided an overall sensitivity above 30% at a
reasonable specificity. However, seven hypermethylated promoter regions (ALX4, BMP3,
NPTX2, RARB, SDC2, SEPT9, and VIM) along with the covariates sex and age yielded an
optimism corrected AUC of 0.86 for all stage CRC and 0.85 for early stage CRC. Overall
sensitivity for CRC detection was 90.7% at 72.5% specificity using a cut point value of 0.5.
Conclusions
Individual hypermethylated DNA promoter regions have limited value as CRC screening
markers. However, a panel of seven hypermethylated promoter regions show great promise
as a model for CRC detection.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers, reaching annual incidence rates of
>1.3 million cases worldwide [1]. Ensuring survival of CRC patients relies on detection at early
stages, which can be achieved through population-based screening [2,3]. The current screening
program in Denmark includes an immunochemical faecal occult blood test (iFOBT) followed by a
colonoscopy if iFOBT is positive.[3] However, patient adherence to current screening programs is
limited by low completion rates with great differences between ethnic groups [4]. This necessitates
the development of other methods for early CRC detection in order to ensure patient survival.
Cell-free nucleic acids are currently of great interest as blood-based biomarkers for cancer, as these
might be more specific for individual cancer types than protein-based biomarkers [5]. Methylation
occurs across the whole genome with the exception of gene promoter regions which are preferably
hypomethylated. Hypermethylation of the gene promoter regions induces gene silencing in two
ways: (i) inhibition of transcription factor binding, and (ii) binding of methyl-binding domain pro-
teins, which enable chromatin modifications. DNA hypermethylation occurs early and often in the
adenoma to carcinoma sequence promoting it as an ideal blood-based biomarker for CRC. This
has led to the development of a commercially available blood test for DNA methylation analysing
the promoter for the SEPT9 gene [6]. However, evaluation of the SEPT9 assay in a large-scale
cross-sectional study revealed sub-optimal sensitivity and specificity (48.2% and 91.5% respec-
tively) [7]. Other case-control studies analysing a larger panel of genes, have revealed more promis-
ing results, however, these studies are often small and lack well-defined control groups [8].
The aim of this study was to evaluate the performance of a panel of hypermethylated pro-
moter regions in plasma for CRC detection, in order to enable blood-based CRC screening.
Methods
Study population
This was a cross-sectional study analysing the ability of plasma derived cell-free DNA hyper-
methylation to distinguish patients with CRC from a control group of patients suspected for but
without CRC. Between 2003 and 2005 at The Department of Gastrointestinal Surgery, Aalborg
University Hospital, a consecutive series of CRC patients were included to evaluate the correla-
tion between coagulation status and CRC. The inclusion of the patients is described elsewhere
[9]. All patients with diagnosed CRC and available blood samples at the time of inclusion were
included in the current study. During the same study period, blood samples from patients
referred for colonoscopy with symptoms of, but without CRC were also collected. These
patients were of a similar age as the CRC patients, and constituted the control group.
We classified patient tumours according to the tumour, node, and metastasis (TNM) sys-
tem, and staging was in accordance with the American Joint Committee on Cancer staging
system (AJCC) 7th Edition.
Written informed consent was obtained from all patients, and the initial study was
approved by The North Denmark Region Committee on Health Research Ethics (N-
20040067). The subsequent hypermethylation analysis was also approved by The North Den-
mark Region Committee on Health Research Ethics (N-20140064) and registered at Clinical-
Trials.gov (NCT02928120).
Outcome and predictor variables
We aimed to establish a multivariable prediction model for CRC detection using a panel of 30
promoter regions, previously evaluated in stool or blood, as biomarkers for CRC with varying
sensitivities [10]. Thus, we defined the outcome variable as patients with/without CRC.
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Along with the covariates sex and age, these 30 hypermethylated promoter regions were the
potential predictor variables. A list of the gene names and their function is provided in the sup-
plementary material (S1 Table).
Blood sampling
Blood samples from the CRC patients were obtained at the time of diagnosis and before any
kind of treatment. Blood samples from the control group were obtained prior to colonoscopy.
Blood sampling was conducted in accordance with The European Concerted Action on
Thrombosis (ECAT) procedures. All blood samples were centrifuged at 4˚C for 20 minutes at
4000 rpm and the plasma samples were immediately stored at -80˚C for future use. The period
from sample acquisition to storage never exceeded two hours.
Hypermethylation analysis
The method for DNA extraction and methylation analysis is based on a rapid bisulphite-treat-
ment protocol described by Pedersen et al. (2012) [11]. A schematic overview of the experi-
mental protocol is appended in the supplementary material (S1 Fig).
Plasma nucleic acids were extracted from 450–1000 μl plasma samples using The easy-
MagTM platform (NucliSens1 [bioMérieux SA, France]) according to the manufacturers’
instructions. The purified nucleic acids were eluted in 35 μl elution buffer (NucliSens1 [bio-
Mérieux SA, France]). Five μl DNA extract were used for quantitation. The remaining 30 μl
was mixed with 60 μl deamination solution, deaminated for 10 minutes at 90˚C, followed by a
purification step (using the easyMagTM platform) and lastly eluted in 25 μl 10 mM KOH. In
order to expand the deaminated DNA, we conducted a first round polymerase chain reaction
(PCR) using a mix of methylation specific outer primers for all the investigated promoter
regions. The reaction buffer (25 μl) consisted of PCR buffer, 13 μM MgCl2, 0.6 mM dNTP
(dTTP is replaced by dUTP), 250 nM of each outer primer, 1.5 U Taq polymerase (BIOTAQTM
[Bioline1, Taunton, MA, USA]), and 0.3 U Cod Uracil-DNA Glycosylase (Cod UNG [Arctic-
Zymes1, Tromsoe, Norway]) in order to limit the risk of contamination in the two step PCR.
We distributed the first round reaction mix to individual 200 μl PCR tubes, which were incu-
bated for five minutes at 37˚C, followed by 95˚C for five minutes, and cooled to room temper-
ature. Thereafter, we added 25 μl of purified deamination product to each tube yielding a
reaction volume of 50 μl. For the second PCR, we distributed 10 μl buffer containing 0.4 μM
methylation specific inner primers and probes in 30 individual wells in a 96 well PCR plate.
We added 10 μl of the first round PCR product to 710 μl preincubated reaction mix (37˚C for
five minutes and 95˚C for 10 minutes) containing PCR buffer, 250 μM dNTP, 10 μM MgCl2, 8
U Taq polymerase (BIOTAQTM [Bioline1, Taunton, MA, USA]), and 0.8 Uracil-DNA Glyco-
sylase (Invitrogen1, Waltham, MA, USA). Twenty μl of reaction mix was then added to each
of the 30 wells to a final reaction volume of 30 μl.
All hypermethylation specific primer and probe sequences along with amplicon sizes are
available in the supplementary material (S2 and S3 Tables).
Statistical analysis
We handled the outcome variable (CRC/no CRC) and the potential predictor variables: hyper-
methylated DNA promoter regions (hypermethylated/not hypermethylated), CEA-levels
(>/ 5 ng/ml, sex (male/female), and age (age>66/age66) as binary variables. This rendered
the data suitable for logistic regression modelling. We used all the patients in the model devel-
opment process and the subsequent cross-validation.
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First, we calculated the median and range of the number of hypermethylated promoter
regions and cell-free DNA concentrations according to CRC patients and controls. We com-
pared the two patient groups using the non-parametric Wilcoxon-Mann-Whitney test. Sec-
ondly, using logistic regression, we performed a univariate screening of potential predictors
according to the outcome variable at a significance level of p = 0.3. Thirdly, we constructed a
multivariable logistic regression model, using stepwise backwards selection. Receiver operating
characteristic (ROC) curves are presented and the area under the ROC curve (AUC) calcu-
lated. Interactions were evaluated between all the potential predictor variables included in the
final model. All models were evaluated using Hosmer-Lemeshow’s goodness of fit test.
Fourthly, we computed a Penalized regression model using Firth’s method with backwards
selection, to assess the impact of separation issues on the model building process. Lastly, we
performed internal validation using “Leave pair out cross validation” computing the optimism
corrected AUC in order to evaluate the predictive performance of the final prediction model.
The predictive performance of the final model was evaluated for all patients and after restric-
tion to early-stage CRC patients (stage I-II).
We used STATA1 V.13.1 (StataCorp LP, TX, USA) for all statistical analyses.
Results
Study population
Review of the CRC patients led to the exclusion of twelve patients: seven with benign disease
or non-colorectal cancer, three did not have any residual cancer after endoscopic resection,
one patient initially refused surgery, and one patient did not provide informed consent. Five
additional patients were excluded, because the reference gene could not be amplified during
PCR analysis (S2 Fig). Review of the control patients lead to the exclusion of five patients with
inflammatory bowel disease and 27 patients diagnosed with any kind of neoplastic disease in
the years following inclusion. This left blood samples from 193 CRC patients and 102 controls
without CRC. The remaining control group included 33 patients with resectable adenomas,
none of which were of high-grade dysplasia. Patient characteristics are provided in Table 1.
Model development
The hypermethylation status of all the promoter regions is provided in Table 2. The median
number (range) of hypermethylated promoters were four (1–11) in the control group and five
(0–28) in the CRC group (p = 0.212) (Fig 1). The median level of cell-free DNA was 4.10 ng/
ml (0.31–52.19) in the control group compared with 4.00 ng/ml (0.26–132.58) in the CRC
group (p = 0.982).
The initial univariate screening left 19 of the potential predictor variables along with sex
and age>66 for further analysis. The logistic regression with stepwise backwards selection is
visualised in Fig 2. Model 12 was considered the most applicable, because it contained a lim-
ited number of genes and the model did not differ from the model produced by Penalized
regression using Firth’s method. Incorporation of CEA as a binary variable (>5 ng/ml) in the
stepwise selection process did not lead to a difference in marker selection.
None of the prediction models showed a significant lack of model fit at the 0.05 significance
level.
Model performance
Model 12 which included seven hypermethylated gene promoter regions (ALX4, BMP3,
NPTX2, RARB, SDC2, SEPT9, and VIM) and the covariates: sex(female) and age>66 had the
Hypermethylated DNA, a biomarker for colorectal cancer
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ability to distinguish CRC patients from patients without CRC with an optimism-corrected
AUC of 0.860 (optimism = 0.027) (Fig 3A). There was a significant interaction between the
prediction markers RARB and VIM (p<0.001). However, inclusion of the interaction in the
model only provided modest information (optimism corrected AUC = 0.869). The interaction
was therefore omitted from the final model.
Removal of the 33 patients with adenomas from the control group did not alter the efficacy
of the prediction model (optimism corrected AUC = 0.863).
In order to characterise Model 12’s performance for early stage cancers, we evaluated the
model by removing the patients with stage three and four CRC. This rendered an optimism-
corrected AUC of 0.853 (optimism = 0.025) (Fig 3B).
The sensitivity, specificity, positive and negative predictive values of Model 12 for CRC
detection in all stages and early stages only, were calculated from the ROC analysis using a 0.5
cut point value. This cut point value led to the most accurate classification of the cancer
patients and the controls. The values are provided in Table 3.
Table 1. Patient characteristics.
Colorectal Cancer Healthy Controls
N 193 102
Age, mean (SD) 67.5 (11.5) 64.7 (14.2)
Sex, n (%)
Male 119 (61.7) 55 (53.9)
Female 74 (38.3) 47 (46.1)
Smoke status, n (%)
Never smoker 68 (35.7) 31 (30.4)
Current smoker 77 (39.9) 28 (27.5)
Previous smoker 43 (22.3) 24 (23.5)
Unknown 5 (2.6) 19 (18.6)
CEA-levels
 5 ng/ml 141 (73.1) 91 (89.2)
> 5 ng/ml 52 (26.9) 11 (10.8)
Tumour, n (%)
T1 3 (1.6) - -
T2 30 (15.5) - -
T3 120 (62.2) - -
T4 34 (17.6) - -
T-unknown 6 (3.1) - -
Node, n (%)
N0 121 (62.7) - -
N1 38 (19.7) - -
N2 28 (14.5) - -
N-unknown 6 (3.1) - -
Metastasis, n (%)
M0 159 (82.4) - -
M1 34 (17.6) - -
Note. The number (N) of patients in each patient group along with the mean age and standard deviations
(SD) in each group. The number (n) and percentages (%) of patients according to sex, smoke status and
carcinoembryonic antigen levels along with the colorectal cancer patients according to the tumour, node,
and metastasis (TNM) classification system is also presented.
https://doi.org/10.1371/journal.pone.0180809.t001
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We also assessed the putative effect of PCR cycle numbers on the results of the assay,
between CRC patients and controls. We classified the promoter regions into groups according
to their cycle threshold values (0, 0–25, 25–30, and>30) (S4 Table). The distribution shows
some difference in cycle threshold value between CRC patients and controls. However,
because of limited power, the effect of this difference could not be evaluated in the multivari-
able logistic regression model.
Discussion
In this study, we analysed a panel of 30 genes previously found to be hypermethylated in
patients with CRC and other neoplasia. Through multivariable logistic regression, we selected
seven gene promoter regions (ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, and VIM), which
Table 2. Hypermethylation status according to gene names.
Colorectal Cancer (N = 193) Healthy controls (N = 102)
N % (95% CI) N % (95% CI)
ALX4 55 28.5 (22.2 35.4) 1 1.0 (0.0 5.3)
APC 81 42.0 (34.9 49.3) 33 32.4 (23.4 42.3)
BMP3 55 28.5 (22.2 35.4) 11 10.8 (5.5 18.5)
BNC1 23 11.9 (7.7 17.3) 13 12.7 (7.0 20.8)
BRCA1 49 25.4 (19.4 32.1) 22 21.6 (14.0 30.8)
CDKN2A 18 9.3 (5.6 14.3) 4 3.9 (1.1 9.7)
HIC1 11 5.7 (2.9 10.0) 1 1.0 (0.0 5.3)
HLTF 22 11.4 (7.3 16.7) 4 3.9 (1.1 9.7)
MGMT 11 5.7 (2.9 10.0) 1 1.0 (0.0 5.3)
MLH1 87 45.1 (37.9 52.4) 44 43.1 (33.4 53.3)
NDRG4 18 9.3 (5.6 14.3) 0 0.0 (0.0 3.6)
NPTX2 135 69.9 (62.9 76.3) 60 58.8 (48.6 68.5)
NEUROG1 40 20.7 (15.2 27.1) 20 19.6 (12.4 28.6)
OSMR 22 11.4 (7.3 16.7) 7 6.9 (2.8 13.6)
PHACTR3 28 14.5 (9.9 20.3) 6 5.9 (2.2 12.4)
PPENK 20 10.4 (6.4 15.6) 4 3.9 (1.1 9.7)
RARB 49 25.4 (19.4 32.1) 71 69.6 (59.7 78.3)
RASSF1A 22 11.4 (7.3 16.7) 16 15.7 (9.2 24.2)
SDC2 47 24.4 (18.5 31.0) 6 5.9 (2.2 12.4)
SEPT9 47 24.4 (18.5 31.0) 5 4.9 (1.6 11.1)
SFRP1 42 21.8 (16.2 28.3) 7 6.9 (2.8 13.6)
SFRP2 39 20.2 (14.8 26.6) 18 17.6 (10.8 26.4)
SPG20 30 15.5 (10.7 21.4) 12 11.8 (6.2 19.6)
SST 58 30.1 (23.7 37.1) 32 31.4 (22.5 41.3)
TAC1 102 52.8 (45.6 60.1) 48 47.1 (37.1 57.2)
THBD 19 9.8 (6.0 14.9) 1 1.0 (0.0 5.3)
TFPI2 14 7.3 (4.0 11.9) 2 2.0 (0.2 6.9)
VIM 34 17.6 (12.5 23.7) 12 11.8 (6.2 19.6)
WIF1 19 9.8 (6.0 14.9) 4 3.9 (1.1 9.7)
WNT5A 12 6.2 (3.3 10.6) 5 4.9 (1.6 11.1)
Note. The number (N) of patients in each patient group along with the percentages (%) of patients according to each hypermethylated promoter region
along with the number (n) of patients with corresponding 95% confidence intervals (95% CI)
https://doi.org/10.1371/journal.pone.0180809.t002
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could distinguish early stage CRC patients from a colonoscopy verified CRC free control
population.
Epi proColon1 (Epigenomics AG Corporation, Berlin, Germany) is the only commercially
available blood based DNA hypermethylation screening test for CRC. The test is based on
SEPT9 hypermethylation, and even though there are promising results, there are still some
drawbacks. In a large cross-sectional study of 1,516 patients scheduled for colonoscopy, the
assay alone only reached a sensitivity of 48.2% at 95.1% specificity, showing the apparent lack
of sensitivity as an individual CRC biomarker [7]. We examined the SEPT9 v2 promoter,
which is methylated in ~90% colorectal malignant and premalignant lesions [12]. Our study
confirmed that hypermethylation of SEPT9 measured in plasma is more frequent in CRC
patients, but an acceptable sensitivity was only achieved with SEPT9 included as part of a larger
panel of hypermethylated promoter regions. The best individual marker was ALX4, however,
with limited sensitivity (sensitivity of 28.5% at 99.0% specificity), further emphasising the need
for a multigene hypermethylation panel for CRC detection.
Interestingly, RARB hypermethylation was a protective factor, more frequently hyper-
methylated in healthy controls (69.6%), compared to patients with CRC (25.0%). This is in
contrast with the fact that RARB has been found to be preferentially hypermethylated in early
stage rectal tumours along with high-grade cervical intraepithelial lesions and high-risk pros-
tate cancer [13,14]. Since T3 tumours represent the bulk of our CRC cohort, along with the
fact that RARB methylation is lost through the progression of rectal tumours, our results could
indicate that RARB hypomethylation is a biomarker for late stage CRC [15].
We also analysed the hypermethylation frequencies of BMP3 and NDRG4—the two genes
implemented in the Cologuard1 (Exact Sciences Corporation, Madison, WI, USA) stool based
CRC screening assay. BMP3 reached our gene panel for CRC detection, and while NDRG4 was
exclusively hypermethylated in CRC patients, it was only positive in 9.3% of cases and thus,
Fig 1. Number of methylated promoter regions according to patient group.
https://doi.org/10.1371/journal.pone.0180809.g001
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not implemented in the model. Whether this difference is due to the media of choice (blood
vs. stool) or other factors remains to be elucidated. The use of stool could provide increased
DNA for analysis as colonic epithelial cells undergo anoikis. Moreover, the molecular charac-
teristics of colorectal tumour cells is influenced by their location inside the tumour—either at
the luminal front or the invasion front [16,17]. The limited sensitivity of NDRG4 in plasma
could also be due to some of the factors listed in the section below.
Even though our panel of promoter regions resemble those analysed by others, there seems
to be a rather large gap in both marker selection and performance. Lee et al found, that APC,
MGMT, RASSF2A, and WIF1 had a sensitivity of 86.5% with a specificity of 92.1% [8]. We eval-
uated three of these gene promoter regions, through our multivariate logistic regression. None
reached the final model. The marker SDC2 was found through an epigenome wide association
study and evaluated in serum samples, revealing a sensitivity of 92.3% for stage I CRC at a
specificity of 95.2% [18]. Our results on SDC2 are more modest with a sensitivity and specific-
ity of 24.0% and 94.1% respectively. The differences in marker performance may be due to dif-
ferences in ethnicity and choice of control population. The control population in the study by
Lee et al. was only specified as Asian patients undergoing a regular health check, whereas our
Fig 2. Stepwise backwards selection according to model number. Note. Logistic regression modelling with stepwise backwards selection. Potential
predictor variables are located in the top row. Model number is recorded in the left column. Area under the receiver operating curve (AUC) according to
model number and the P-value according to the removed predictor variable is located in the two rightward columns.
https://doi.org/10.1371/journal.pone.0180809.g002
Hypermethylated DNA, a biomarker for colorectal cancer
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Fig 3. Receiver operating characteristics curves for colorectal cancer. Note. A) ROC curve for all stage
CRC with a non-optimism corrected AUC of 0.8870. B) ROC curve for stage I and II CRC with a non-optimism
corrected AUC of 0.8775. Receiver operating characteristics (ROC). Colorectal cancer (CRC). Area under the
receiver operating characteristics curve (AUC).
https://doi.org/10.1371/journal.pone.0180809.g003
Hypermethylated DNA, a biomarker for colorectal cancer
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population is from a Caucasian patient cohort of similar age and gender referred for colonos-
copy with CRC symptoms.
Limitations
There are some limitations to our analytical setup.
Hypermethylated DNA promoter regions, other than the 30 included in our initial screen-
ing panel, may be more efficient as biomarkers for CRC detection. The gene promoter regions
were initially selected based on a systematic literature search [10]. We used this approach to
evaluate proven CRC hypermethylation biomarkers, previously analysed in tumour remote
media like blood and stool samples. Sequencing methods have since improved, providing new
knowledge of complex genetic and epigenetic disruptions in colorectal carcinogenesis, and the
field of epigenetic research is growing rapidly. Other approaches for the evaluation of hyper-
methylation biomarkers such as the implementation of an epigenome wide association study
could have been used. Whether other DNA hypermethylations are more efficient as cell-free
DNA based biomarkers for CRC remains to be elucidated.
Regarding the differences in marker performance, between previous studies and our cur-
rent study, performance issues could be attributed to analytical limitations. Methylation spe-
cific PCR only enables the analysis of one site in each of the promoter regions, meaning that
any discordance in the choice of primers and probes could lead to different results [19]. Fur-
thermore, we used a rather small amount of plasma (<1ml) for our analysis whereas the new
kit for SEPT9 analysis (Epi proColon1 2.0 [Epigenomics AG Corporation, Berlin, Germany])
isolates DNA from ~5 ml of plasma, which renders more DNA for analysis and possible repli-
cate analysis [20]. This problem is stressed by the fact, that the number of cell-free tumour
DNA fragments per 5 ml could be less than 10 for stage I CRC, making the amount of plasma
used for methylation detection critical [21].
This study was exploratory in order to construct a biomarker panel of hypermethylated
DNA promoter regions for CRC detection. The selection of the prediction markers was made
on the entire cohort, in order to construct the most robust model. To evaluate the inherit prob-
lem of overfitting, we conducted internal validation using “leave pair out cross validation”.
However, before the model can be used in a clinical setting, external validation in an indepen-
dent cohort must be conducted.
Strengths
The major strength of our study is the use of a cohort of consecutive CRC patients and a well-
defined colonoscopy verified cancer-free control group with a comparable age and gender dis-
tribution. Other studies have employed less than optimal control groups, often not described
in more detail than “healthy controls”. We have used patients who, albeit having symptoms,
are an excellent representation of the screening population.
Table 3. Model 12s sensitivity, specificity, PPV, and NPV for CRC.
Sensitivity Specificity PPV NPV
All stage CRC, % 90.7 72.5 6.0 99.8
Stage I and II CRC, % 88.7 73.5 6.1 99.7
Note: All values were calculated using the receiver operating characteristics (ROC) curve analysis at a 0.5 cut point value. The positive predictive values
(PPV) and negative predictive values (NPV) are calculated from the prevalence of colorectal cancer (CRC) in the Danish population above 60 years of age
(~25.000 cases in ~1.4 million people)
https://doi.org/10.1371/journal.pone.0180809.t003
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Another strength of our study is the method used for DNA extraction and bisulphite con-
version for methylation analysis. Previously, the amount of DNA degradation through the
bisulphite treatment was between 84 and 96% [22]. Through an optimized conversion step, we
were able to treat the DNA with bisulphite, with a recovery as high as 60%, enabling us to
detect hypermethylated DNA fragments in the limited amounts of plasma available in our
study.
The development of the prediction model is in full accordance with current guidelines for
the development of biomarkers for outcome detection [23].
Conclusion
In our study, a panel of seven hypermethylated gene promoter regions (ALX4, BMP3, NPTX2,
RARB, SDC2, SEPT9, and VIM) with the covariates: sex and age>66 was able to distinguish
CRC patients from patients suspected for, but without CRC. Importantly, the model also had
the ability of detecting early stage CRC with a similar performance.
This study shows, that no single hypermethylated DNA biomarker can be used in a diag-
nostic setting for CRC, but a panel of such may be of greater clinical interest. External valida-
tion in future studies would ensure that the diagnostic performance is reproducible.
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